Thermo Fisher Scientific Inc. (NYSE:TMO) is Lathrop Investment Management Corp’s 8th Largest Position

Lathrop Investment Management Corp lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 32,255 shares of the medical research company’s stock after selling 381 shares during the quarter. Thermo Fisher Scientific comprises approximately 3.5% of Lathrop Investment Management Corp’s holdings, making the stock its 8th largest holding. Lathrop Investment Management Corp’s holdings in Thermo Fisher Scientific were worth $17,121,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Thermo Fisher Scientific by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 32,760,738 shares of the medical research company’s stock worth $16,582,503,000 after acquiring an additional 180,618 shares in the last quarter. Morgan Stanley raised its position in shares of Thermo Fisher Scientific by 0.4% in the 3rd quarter. Morgan Stanley now owns 12,418,429 shares of the medical research company’s stock valued at $6,285,838,000 after purchasing an additional 50,736 shares in the last quarter. Northern Trust Corp raised its position in shares of Thermo Fisher Scientific by 2.6% during the 3rd quarter. Northern Trust Corp now owns 3,929,225 shares of the medical research company’s stock valued at $1,988,856,000 after acquiring an additional 99,377 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Thermo Fisher Scientific by 9.8% during the 3rd quarter. Wellington Management Group LLP now owns 3,080,687 shares of the medical research company’s stock valued at $1,559,351,000 after acquiring an additional 274,464 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Thermo Fisher Scientific by 0.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,184,928 shares of the medical research company’s stock valued at $1,105,945,000 after acquiring an additional 8,672 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Up 0.3 %

Shares of NYSE TMO traded up $1.87 during mid-day trading on Friday, hitting $573.60. 1,438,184 shares of the company traded hands, compared to its average volume of 1,317,052. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The stock has a market capitalization of $218.95 billion, a price-to-earnings ratio of 36.79, a PEG ratio of 2.41 and a beta of 0.80. The company has a quick ratio of 1.39, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. The business has a 50 day moving average of $573.60 and a two-hundred day moving average of $529.90.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating the consensus estimate of $4.70 by $0.41. The business had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.54 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were paid a $0.39 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on TMO shares. Raymond James upped their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. HSBC increased their price target on Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. Barclays increased their price target on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research note on Thursday. Royal Bank of Canada increased their price target on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Finally, JPMorgan Chase & Co. increased their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $606.76.

Insider Buying and Selling

In related news, Director Debora L. Spar sold 164 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the transaction, the chief executive officer now owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Debora L. Spar sold 164 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the transaction, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,277 shares of company stock valued at $28,513,384. Corporate insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.